<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543933</url>
  </required_header>
  <id_info>
    <org_study_id>07-491</org_study_id>
    <nct_id>NCT00543933</nct_id>
  </id_info>
  <brief_title>Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease</brief_title>
  <official_title>Acute Effect of Inhaled Nitric Oxide on Pulmonary Insufficiency in Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhaled nitric oxide in patients with pulmonic valve insufficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonic valve insufficiency (PI) is a well-defined problem after primary surgical repair of&#xD;
      Tetralogy of Fallot (TOF). Though well-tolerated for years, long-term PI can lead to&#xD;
      structural changes in the right ventricle, the sequelae of which include right heart failure,&#xD;
      arrhythmia, and sudden cardiac death. The only current treatment for severe symptomatic PI is&#xD;
      pulmonic valve replacement. We hypothesize that inhaled nitric oxide (iNO), a selective&#xD;
      pulmonary vasodilator, can acutely decrease PI as assessed by cardiac magnetic resonance&#xD;
      imaging (CMR). Methods: 22 consecutive patients with PI in the setting of corrected TOF or&#xD;
      post pulmonic valve balloon valvuloplasty will undergo a clinically indicated CMR. Nitric&#xD;
      oxide gas will be delivered via facemask through a specialized delivery device at 40ppm.&#xD;
      After 5 minutes, flow velocity mapping and gradient echo sequences will be repeated to assess&#xD;
      pulmonary regurgitant fraction, right ventricular volumes, and ejection fraction. Nitric&#xD;
      oxide will be discontinued after acquisition of the last picture. Wilcoxon rank-sum for&#xD;
      paired data will be used to assess effect of intervention. Significance: If decreasing&#xD;
      pulmonary vascular resistance decreases PI, medical therapy with long-acting pulmonary&#xD;
      vasodilators may be an attractive therapeutic option with the goal of delaying or even&#xD;
      obviating pulmonic valve replacement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left institution&#xD;
  </why_stopped>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulmonary regurgitant volume and fraction</measure>
    <time_frame>Single time point</time_frame>
    <description>Aortic regurgitant fraction measured by CMR velocity flow mapping</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pulmonary Insufficiency</condition>
  <arm_group>
    <arm_group_label>iNO administered</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iNO administered at 40 ppm via a non-rebreather mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iNO administered</intervention_name>
    <description>iNO at 40 ppm through a non-rebreather mask for 5 minutes</description>
    <arm_group_label>iNO administered</arm_group_label>
    <other_name>Nitric Oxide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known pulmonary insufficiency status&#xD;
&#xD;
          -  Previous Tetralogy of Fallot repair or balloon valvuloplasty/surgical valvotomy for&#xD;
             pulmonary stenosis&#xD;
&#xD;
          -  Clinically indicated cardiac magnetic resonance imaging study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrollment in another clinical trial&#xD;
&#xD;
          -  Age less then 18 years&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Institutionalized individual&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Serious claustrophobia&#xD;
&#xD;
          -  Pacemaker/ICD&#xD;
&#xD;
          -  Aneurysm clips&#xD;
&#xD;
          -  Internal hardware&#xD;
&#xD;
          -  Severe obesity (&gt;350lbs)&#xD;
&#xD;
          -  Residual ventricular septal defect&#xD;
&#xD;
          -  History of methemoglobinemia&#xD;
&#xD;
          -  History of blood dyscrasias&#xD;
&#xD;
          -  Acute pulmonary infection&#xD;
&#xD;
          -  Pulmonary edema&#xD;
&#xD;
          -  Hypersensitivity to nitric oxide or any of its components&#xD;
&#xD;
          -  Left ventricle dysfunction (EF&lt;40%)&#xD;
&#xD;
          -  Concurrent use of nitroglycerin or prilocaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Krasuski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

